Efficacy and safety of tranexamic acid in patients undergoing surgery for bone and soft tissue tumors: a propensity score matching analysis. (9th May 2022)

• Record Type: Journal Article
• Authors: Oyama, Ryunosuke; Setsu, Nokitaka; Matsumoto, Yoshihiro; Endo, Makoto; Fujiwara, Toshifumi; Iida, Keiichiro; Nabeshima, Akira; Nakashima, Yasuharu
• Is Part Of: Japanese journal of clinical oncology. Volume 52:Number 9(2022)
• Page Start: 1029
• Page End: 1038
• Publication Date: 2022-05-09
• Subjects: tranexamic acid -- tumor -- sarcoma -- propensity score; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyac078
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract: Objective: The aim of this study was to investigate the efficacy and safety of tranexamic acid in patients undergoing surgery for bone and soft tissue tumors. Methods: Data were retrospectively collected from 454 consecutive patients with bone and soft tissue tumors who underwent open biopsy, marginal resection, curettage or wide resection between January 2017 and December 2018. We performed propensity score matching of patients who received tranexamic acid with those who did not. The primary outcome variables were intra-operative, peri-operative and estimated blood loss (IBL, PBL and EBL, respectively). Results: Tranexamic acid (+) and tranexamic acid (−) groups were defined according to whether patients received tranexamic acid or not. Among the 454 patients, open biopsy was performed in 102, marginal resection in 175, curettage in 54 and wide resection in 123. Intra-operative blood loss was significantly lower in the tranexamic acid (+) group than in the tranexamic acid (−) group for both marginal and wide resection (marginal resection: 17.3 vs. 70.3 g, respectively, P = 0.045; wide resection: 128.8 vs. 273.1 g, respectively, P = 0.023). Peri-operative blood loss and estimated blood loss were also significantly lower in the tranexamic acid (+) group for wide resection (peri-operative blood loss: 341.5 vs. 686.5 g, respectively, P = 0.0039; estimated blood loss: 320.7 vs. 550.6 ml, respectively, P = 0.030). No venous thromboembolism occurred in either group. Conclusion: This study suggests that TXA administration safely and effectively reduces blood loss, in particular for wide resection, with no increase in the rate of adverse events. Abstract : TXA administration safely and effectively reduces blood loss in patients undergoing surgery for BSTT with no increase in the rate of adverse events.